Compare GKOS & MTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | MTRN |
|---|---|---|
| Founded | 1998 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Specialties |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.5B |
| IPO Year | 2015 | 2000 |
| Metric | GKOS | MTRN |
|---|---|---|
| Price | $146.06 | $261.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $126.92 | $52.50 |
| AVG Volume (30 Days) | ★ 928.7K | 372.1K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.32% |
| EPS Growth | N/A | ★ 1178.57 |
| EPS | N/A | ★ 0.92 |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $23.32 | $15.31 |
| Revenue Next Year | $27.43 | $7.57 |
| P/E Ratio | ★ N/A | $288.35 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $80.69 |
| 52 Week High | $148.62 | $298.87 |
| Indicator | GKOS | MTRN |
|---|---|---|
| Relative Strength Index (RSI) | 67.05 | 56.01 |
| Support Level | $96.44 | $119.80 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 5.65 | 13.81 |
| MACD | 1.60 | -0.43 |
| Stochastic Oscillator | 98.92 | 38.46 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Materion Corp offers products that include precious and non-precious specialty metals, inorganic chemicals and powders, specialty coatings, specialty engineered beryllium and copper-based alloys, beryllium composites, ceramics, and engineered clad and plated metal systems. Its segments are: Performance Materials provides beryllium and non-beryllium containing alloy systems and custom engineered parts. Electronic Materials produces chemicals, microelectronics packaging, and specialty metal products, including vapor deposition targets and preforms. Precision Optics produces thin film coatings and optical filter materials. The Other reportable segment includes unallocated corporate costs and assets. It operates in the United States, Asia, Europe, and other countries.